EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales

Zhiwei Huang, Xingchen Bian, Yi Li, Jiali Hu, Beining Guo, Xinyi Yang, Yi Jin, Shansong Zheng, Xinmei Wang, Cong Gao, Jing Zhang, Xiaojie Wu

Frontiers in Pharmacology · 11.04.2024 · 15

DOI: 10.3389/fphar.2024.1282480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.04.2024. Verfasst von Zhiwei Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

FL058 is a novel beta-lactamase inhibitor with a broad spectrum of activity and a favorable safety profile. The objective of this study was to evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the combination of FL058 and meropenem in an in vitro infection model.

Methods

By simulating human concentration-time profiles in the in vitro model, meropenem combined with FL058 when administered 1 g/0.5 g, 1 g/1 g, 2 g/1 g, and 2 g/2 g q8h by 3-h infusion achieved approximately 2- and 4-log10 kill to KPC/OXA-producing Klebsiella pneumoniae and Escherichia coli ; the combination therapy could not inhibit NDM-producing K. pneumoniae but could maintain NDM-producing E. coli around a baseline.

Results

The PK/PD indexes that best described the bacterial killing from baseline in log10 CFU/mL at 24 h were the percent time of free drug above the minimal inhibitory concentration (MIC) (%fT > MIC, MIC with FL058 at 4 mg/L) for meropenem and the percent time of free drug above 1 mg/L (%fT > 1 mg/L) for FL058. The targets for achieving a static effect and the 1- and 2-log10 kill were 74, 83, and 99 for %fT > MIC of meropenem and 40, 48, and 64 for %fT > 1 mg/L of FL058, respectively. The PK/PD index of %fT > 1 mg/L can provide a basis for evaluating clinical dosing regimens for FL058 combined with meropenem.

Conclusion

FL058 combined with meropenem might be a potential treatment for KPC- and/or OXA-48-producing Enterobacterales infection.

Schlagwörter

Stichwörter der Autor:innen

beta-lactamase inhibitorcarbapenemase-producing Enterobacteralesin vitro modelmeropenempharmacokinetics/pharmacodynamics

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
  • Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Qilu Pharmaceutical Co Ltd, Jinan, China.

Zitieren

APA

Huang, Z., Bian, X., Li, Y., Hu, J., Guo, B., Yang, X., Jin, Y., Zheng, S., Wang, X., Gao, C., Zhang, J., & Wu, X. (2024). In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1282480

Vancouver

Huang Z, Bian X, Li Y, Hu J, Guo B, Yang X, et al. In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1282480

BibTeX
@article{Huang2024,
  author = {Huang, Zhiwei and Bian, Xingchen and Li, Yi and Hu, Jiali and Guo, Beining and Yang, Xinyi and Jin, Yi and Zheng, Shansong and Wang, Xinmei and Gao, Cong and Zhang, Jing and Wu, Xiaojie},
  title = {In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1282480}
}
Kostenlos starten →